Gilead Sciences (NASDAQ:GILD) has agreed to acquire CymaBay Therapeutics (NASDAQ:CBAY) for a total equity value of $4.3B.

Pursuant to the terms of the merger agreement, a Gilead (GILD) subsidiary will launch a tender offer to acquire all outstanding shares


Source link

You May Also Like

2 Grammy-Nominated Musicians Share What They Consider the Greatest Assets to Any Startup | Entrepreneur

We recently had an amazing conversation about the skincare brand Mother Science…

Imagining new solutions with AI

AI technology is dominating headlines and revolutionizing the way companies operate. From…

This Founder Has Created a System to Help Women Entrepreneurs Manifest Their 2023 Goals

Hilary DeCesare is the founder of The ReLaunch Co., and the author…

House passes bill to avoid rail strike (NYSE:UNP)

Chip Somodevilla/Getty Images News The House passed legislation on Wednesday to avoid…